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GuidelinesAbstract Objective: To probe doctors’ attitudes and reveal wrong perception in the management
of acute gouty attacks.
Design: A descriptive study using a designed questionnaire that was completed through face to face
interviews in hospitals, health units and polyclinics in the Makah Region.
Method: This is a qualitative study of treatment by 99 doctors conducted in the second half of
2012. The sample included orthopedists, rheumatologists, general practitioners and family physi-
cians.
Results: 72 (72.7%) doctors started treatment of acute attacks with mono-therapy. 58 doctors
(58.6%) started with NSAIDs. Indomethacin was the most frequent prescribed NSAIDs. 18 doctors
(18.2%) prescribed Allopurinol as the ﬁrst drug of choice.
42 doctors (43.8%) started Allopurinol ‘‘2 weeks after acute attack’’. 31 doctors (32.3%) mentioned
that they used 100 mg daily dose. 41 doctors (42.7%) mentioned that the starting dose depends on
the patient’s condition. Allopurinol was prescribed once daily by 37 doctors (38.9%). 53 doctors
(55.8%) used Allopurinol as prophylaxis.
The most frequent test requested was a 24-h urine test for uric acid. In case patients were already on
Allopurinol and presented with an acute attack of gout; 33 doctors (34.7%) tended to ‘‘increase the
dose’’.
The most important factor in adjusting the Allopurinol dose is Serum Uric Acid Level. 37 doctors
(39.4%) mentioned that they ask for Serum Uric Acid Level every 3–4 weeks.
122 H. MustafaConclusion: There were common pitfalls that need a training program to increase awareness of
doctors with general guidelines and recommendations. The most critical pitfalls include prescribing
Allopurinol in acute gouty attacks and ignoring the Renal Function Test.
ª 2014 Alexandria University Faculty of Medicine. Production and hosting by Elsevier B.V. All rights
reserved.1. Introduction
Gout is a pathological and clinical disorder which is mainly
characterized by hyperuricemia; which is an increase in serum
urate levels of 7.0 mg/dl in men or greater than 6.0 mg/dl in
women.1,2 Tophi are a pathognomonic feature of gout detect-
able by physical examination and/or by imaging approaches
and pathology examination.3–5 Typically, the disease initially
presents as acute episodic arthritis then manifests as chronic
arthritis of one or more joints.1,2
Gout is one of themost common rheumatic diseases of adult-
hood, with a self-reported prevalence. In USA it was recently
estimated as 3.9% of adults (8.3 million people).6 In Saudi
Arabia, 8.42% of the study population had hyperuricemia but
no case of gout was found.7 Compared with women, men have
a four- to nine-folds increased risk of developing gout.8
1.1. Treatment of acute attacks
The choice mainly depends on whether the patient has concom-
itant health problems or not (e.g.: peptic ulcer or renal insufﬁ-
ciency). There are various treatment options, such as
corticosteroids, NSAIDs, ACTH and colchicine. Colchicine is
now rarely used. An intra-articular steroid injection is preferred
when an easily accessible large joint is involved and when
comorbid conditions exist limiting the use of colchicine and
NSAIDs. Reasonably septic arthritis must be excluded.9–11
Patients with no underlying health problems and having an
acute gouty attack, are usually prescribed with NSAIDs as
drugs of choice. Most NSAIDs can be used, however, indo-
methacin is the NSAID conventionally chosen for acute gout.
An agent with a quick onset of action is selected. Aspirin is not
recommended since it can lengthen and strengthen the acute
attack, since it can change Uric Acid Levels.
1.2. Colchicine
Is now less commonly used than NSAIDs, due to its narrow
therapeutic window and risk of toxicity. Although, it was once
the treatment of choice for acute gout.12,13
1.3. Combination therapy
If thepatientdoesnothave anadequate response to initial therapy
with a single drug, guidelines advice that adding a second appro-
priate agent is acceptable. Using combination therapy from the
start is appropriate for an acute, severe gout attack, particularly
if the attack involves multiple large joints or is poly-articular.14
1.4. Treatment of chronic gout
As ﬁrst line pharmacological approach, guidelines recommend
either Allopurinol or febuxostat with xanthine oxidase inhibi-
tor therapy with gout patients who have renal disease.Guidelines advice, however, state that mono-therapy in
patients with creatinine clearance less than 50 mL/min with
probenecid is not a ﬁrst line choice,15 since probenecid may
also cause drug interactions.
1.5. Prophylaxis
Some drugs can alter the levels of tissue and serum uric acid,
causing acute attacks of gout, such as probenecid, Allopurinol
and febuxostat. Accordingly low dose NSAID or colchicine is
given for 6 months at least in order to decrease this unfavor-
able effect. Low doses of prednisone are sometimes given when
the patients cannot take either colchicine or NSAIDs.
1.6. Allopurinol
It should be started at a low dose of 100 mg per day, but can be
titrated to 800 mg per day as necessary for a patient to achieve
the target SUA level of 6.0 mg/dl.16–18 It has been recom-
mended that patients with renal impairment should receive
lower doses. Allopurinol can be used in combination with pro-
benecid. Stopping Allopurinol is not recommended during
acute attacks.19
Aim of the study to probe doctors’ attitudes and reveal
wrong perception in the management of acute gouty attacks.2. Methodology
This is a qualitative research in which 99 physicians were
face-to-face interviewed through a structured questionnaire.
Physicians were from the Makah Region – Saudi Arabia and
essentially involved in gout management. Interviews were
conducted in the second half of 2012.
The objective of the study is to describe physicians’ pre-
scribing habits in the treatment of gout and whether or not
matching the general guidelines and recommendations.
The sample included orthopedists, rheumatologists, general
practitioners and family physicians withdrawn from hospitals,
health units and polyclinics.3. Results
99 doctors were asked 17 questions about their experience with
acute gout attack.
Table 1 shows treatment of choice; mono vs. combined
therapy, ﬁrst line of choice and ﬁrst NSAID of choice.
The most common indication of initiating urate lowering
agents in patients with acute gouty attack is Serum Uric Acid
Level, mentioned by 67 doctors (68.4%) followed by the pres-
ence of Tophi (44–44.9%), history of Renal Stones (41–41.8%)
and history of 2 or more severe attacks (36–36.7%). Less fre-
quent indications are history of renal failure (28–28.6%),
Table 1 Treatment of choice of acute gouty attacks; mono vs.
combined therapy, ﬁrst line of choice and ﬁrst NSAID of
choice.
Number %
Choice of mono vs. combined therapy
Mono-therapy 72 72.7
Combined therapy 27 27.3
Total 99 100
First treatment of choicea
NSAIDs 58 58.6
Oral Colchicine 34 34.3
Allopurinol 18 18.2
Steroid 14 14.1
Uricosuric Agent 7 7.1
IV Colchicine 6 6.1
None 1 1.0
Total 138.00 139.4










Total Responses 109 110
Others include; Paracetamol and colchicine.
a Each doctor mentioned an average of 1.39 treatments.
b Each doctor mentioned an average of 1.10 NSAIDs.
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(19–19.4%), age (15–15.3%), history of co-morbid diseases
(14–14.3%) and history of severe single attack (13–13.3%).
The least frequent indications were sex, thyroid disease, spe-
ciﬁc indication and race. Each doctor mentioned an average
of 3.2 indications.
Table 2 shows the use of ULT; Treatments used as a pro-
phylaxis to prevent recurrent attacks, when doctors start
ULT, Starting Dose of ULT (Allopurinol) and Frequency of
using ULT per day.
Table 3 shows tests that doctors like to order in following
up patients.
In case the patient was already on Allopurinol and pre-
sented with an acute attack of gout, 33 doctors (34.7%) tend
to ‘‘increase the dose’’, 30 doctors (31.6%) tend to ‘‘stop it
and continue after the attack’’, 23.2% tend to ‘‘continue on
the same dose’’, 5.3% ‘‘decrease the dose’’ and 5.3% will stop
it completely.
The most important factor in adjusting Allopurinol dose is
the Serum Uric Acid Level, mentioned by 76 doctors (79.2%),
Renal Function (serum creatinine) mentioned by 56 doctors
(58.3%), ‘‘number of attacks’’ mentioned by 27 doctors
(28.1%) and ‘‘24-h Urine Uric Acid Level’’ mentioned by 25
doctors (26%). Each doctor mentioned an average of 1.91
answers.
Frequency of serum uric acid test; 1 doctor (1.1%) ‘‘every
1–2 weeks’’, 37 doctors (39.4%) mentioned ‘‘every 3–4 weeks’’,
19 doctors (20.2%) ‘‘every 5–6 weeks’’, 29 doctors (30.9%)
‘‘every 7–8 weeks’’ and 8 doctors (8.5%) mentioned that they
do not use it for follow up.
The most important precipitating factors that doctors con-
sider are Alcohol (mentioned by 60 doctors 62.5%), obesity
(53–55.2%), thiazide or lasix (48–50%) and low dose of aspirin
(18–18.8%).
Factors which are considered when prescribing uricosuric
agents are; Renal Function Tests (mentioned by 73 doctors –
76%), History of Renal Stones (57–59.4%), Measuring 24-h
Urine Uric Acid (39–40.6%) and age (31–32.3%). Each doctor
mentioned an average of 2.15 answers.
4. Discussion
A sample of 99 doctors from the Makah Region were face-to-
face interviewed to describe their attitudes in the management
of acute gouty attacks and to ﬁnd out whether doctors follow
general guidelines and recommendations or not.
72 doctors (72.7%) started the treatment of acute gouty
attacks with mono-therapy which matches to general guide-
lines and recommendations.15
58 doctors (58.6%) started treatment with NSAIDs which
matches the guidelines. 34 doctors (34.3%) use Oral Colchicine
which is the second choice of general guidelines and recommen-
dations. 18 doctors (18.2) use Allopurinol which is not recom-
mended by the guidelines in acute attacks and is considered a
big mistake in the management of acute attacks and 14 doctors
(14.1%) use steroids which is the third choice of the guidelines.15
Indomethacin is the most frequent prescribed NSAID,
mentioned by 41 doctors (41.8%) followed by Profen and Dic-
lofenac by 21 doctors (21.4%) for each of them followed by
Meloxicam by 10 doctors (10.1%) and Celecoxib & Naproxen
by 6 doctors (6.1%) for each of them (Table 1).Only 53 doctors (55.8%) used Allopurinol as prophylaxis to
prevent recurrent attacks which matches with guidelines. 22
doctors (23.2%) use uricosuric agents, 16 doctors (16.8%) Col-
chicine and 12 doctors (12.6%) use NSAIDs.16–18
42 doctors (43.8%) started Allopurinol 2 weeks after acute
attack which matches with guidelines. On the other hand, 12
doctors (12.5%) started Allopurinol 4-weeks later, 29 doctors
(30.2%) started Allopurinol ‘‘Immediately’’ which is also a
common mistake and does not match the guidelines.16–18
General guidelines and recommendations advise that the
dosage of Allopurinol should be started at a low dose of
100 mg per day.16–18 Only 31 doctors (32.3%) mentioned that
they started with a 100 mg dose while 9 doctors (9.4%) started
with 200 mg and 18 doctors (18.8%) started with 300 mg/day.
41 doctors (42.7%) refused to recommend a certain dosage as a
starting dose as it depends on the patient’s condition.
Allopurinol is prescribed once daily by 37 doctors (38.9%),
which matches with guidelines. BID is reported by 16 doctors
(16.8%) and TID by 6 doctors (6.3%). 33 doctors (34.7%)
mentioned that it depends on the case while 3 doctors
(3.2%) do not use Allopurinol.
Only 44 doctors (45%) consider the Serum Creatinine
(Renal Functions) test as a very important test in Allopurinol
dose adjustment (Table 3).
Guidelines advise not to stop Allopurinol in case the
patient is presented by an acute attack of gout and is already
on Allopurinol.19 However, in our study the results have
Table 2 The use of urate lowering therapy.
Number %
Treatments used as a prophylaxis to prevent recurrent attacksa
Base 95
Allopurinol (ULT) 53 56





Total responses 116 122
When doctors start ULTb
Base 99
Immediately 29 29
2 weeks later 42 42
4 weeks later 12 12
Other 14 14
Don’t use ULT 2 2
Total responses 99 100
Starting dose of ULT (Allopurinol)c
Base 99
100 mg 31 31
200 mg 9 9
300 mg 18 18
Depend on the case 41 41
Total responses 99 100
Frequency of using ULT per day
Base 95
Once daily 37 39
Two times daily 16 17
Three times daily 6 6
Depend on the case 33 35
Don’t use ULT 3 3
Total Responses 95 100
a Each doctor mentioned an average of 1.22 treatments. Others
include; diet and according to urine uric acid levels.
b Others include; 2 or more severe attacks according to 24 h urine
uric acid , according to Uric Acid Level, after 6 months, after sta-
bilization in hospital, after the acute attack subsided, depends on
the case, 3 weeks later.
c Each doctor mentioned an average of 1.05 answers.
Table 3 Tests used to follow up.
Number %
Base 97
24 h urine uric acid 62 64
Joint X-ray 49 51
Serum creatinine (Renal Functions) 44 45
Urine analysis 36 37
CBC 27 28
Liver function tests 20 21
Ca level 15 15
ECG 3 3
Others 12 12
None of them 6 6
Total responses 274 282
Each doctor mentioned an average of 2.82 tests.
Others include; serum uric acid, joint ﬂuid, ESR and urine.
124 H. Mustafashown that 23.2% of the doctors ‘‘continue on the same dose’’,
34.7% tend to ‘‘increase the dose’’, 31.6% tend to ‘‘stop it and
continue after the attack’’, 5.3% ‘‘decrease the dose’’ and 5.3%
will ‘‘stop it completely’’. Renal Function Tests and serum uric
acid are important factors in adjusting the Allopurinol dose.
Only 79.2% of the doctors reported the Serum Uric Acid
Level, 58.3% mentioned Renal Function (creatinine), 28.1%
mentioned ‘‘number of attacks’’ and 26% mentioned ‘‘24-h
urine Uric Acid Level’’.15
Guidelines recommend testing the Uric Acid Level every 3–
4 weeks to adjust the Allopurinol dose. Only 37 doctors
(39.4%) mentioned ‘‘every 3–4 weeks’’, 19 doctors (20.2%)
‘‘every 5–6 weeks’’, 29 doctors (30.9%) ‘‘every 7–8 weeks’’
and 1 doctor (1.1%) ‘‘every 1–2 weeks’’. 8 doctors (8.5%) men-
tioned that they do not use it for follow up.19
Factors which are considered when prescribing uricosuric
agents are; Renal Function Tests (mentioned by 73 doctors –
76%), History of Renal Stones (57–59.4%), measuring 24-h
urine uric acid (39–40.6%) and Age (31–32.3%), which does
not match with general guidelines and recommendations.16–185. Conclusion
A considerable number of doctors do not follow general guide-
lines and recommendations in managing acute gouty attacks.
There were common pitfalls that need a training program to
increase the awareness of doctors with the general guidelines
and recommendations.
Common pitfalls were
 Management of acute attacks:
s ULT (Allopurinol) should not be given in acute gouty
attacks: 18% of doctors reported that their ﬁrst drug
of choice in acute attack is Allopurinol and 29% repo-
rted that they use Allopurinol immediately in acute
attacks.15
s Mono-therapy is recommended to start with in acute gouty
attacks. 27% of doctors start with combined therapy in
acute attacks.15
 Prophylaxis therapy:
s ULT (Allopurinol) is the drug of choice in prophylaxis
against recurrent acute attacks. After the resolution of
the acute attack, only 53 doctors (56% of doctors) rep-
orted that they use Allopurinol as prophylaxis.16–18
s Allopurinol therapy (ULT) should be started 2-weeks after
acute attack as a prophylaxis therapy to prevent recur-
rence. Only 44% started Allopurinol ‘‘2-weeks after ac-
ute attack’’.16–18
s Allopurinol should be started at a low dose of 100 mg/day.
Only 32% of doctors mentioned that the starting dose of
Allopurinol is 100 mg daily.16–18
s Allopurinol should be given once daily (OD). Only 39% of
doctors reported that they prescribe Allopurinol once
daily.19
 Allopurinol and recurrent attacks:
s In case the patient was already onAllopurinol and presented
with an acute attack of gout, Allopurinol should be ‘‘con-
tinued in the same dose’’. Only 23% of doctors mentioned
that they will ‘‘continue in the same Dose’’.16–18
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s Serum uric acid is essential in Allopurinol dose adjust-
ment. Only 79% of doctors asked for Serum Uric Acid
Level to adjust the dose of Allopurinol.15
s Serum Uric Acid Level testing should be repeated ‘‘every
3–4 weeks’’. Only 39% of doctors mentioned that they
repeat Uric Acid Level testing ‘‘every 3–4 weeks’’ to
adjust the dose of Allopurinol in order to achieve the
targeted Uric Acid Level (less than 6mg/dl).19
s Renal Function Test is essential in Allopurinol dose adjust-
ment. Only 58% of doctors asked for Renal Function
Tests to adjust the dose of Allopurinol.16–18
Recommendations
Increase the level of awareness, by doing seminars and printing
brochures to correct these misconceptions and pitfalls. Further
studies are recommended.
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